Gilead Sciences breaks ground on new manufacturing hub

4 September 2025

US antivirals specialist Gilead Sciences (Nasdaq: GILD) yesterday celebrated the ground-breaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters.

This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities.

Without saying how much was being spent, Gilead explained that it is part of its planned $32 billion investment in US innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America’s biopharmaceutical leadership while fueling high-quality jobs, research, and domestic manufacturing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK